Previsioni

Il prezzo obiettivo medio degli analisti è +16,74€ (+23,09%). La mediana è +16,74€ (+23,09%).

Acquista	5
Mantieni	6
Vendi	0

Notizie Vai al feed delle notizie

AngioDynamics deepens strategy shift toward MedTech growth, CEO Clemmer to step down

At the Canaccord Genuity conference, AngioDynamics presented an increased focus on a high-growth MedTech portfolio: MedTech revenue rose 18% in 2026 and now represents 47% of total revenue. For fiscal 2027, management expects MedTech growth of 12–15%, a gross margin of 54–55% and adjusted EBITDA of $13–16 million; tariffs continue to weigh on results by about $4 million. Core growth drivers are the Auryon platform, mechanical thrombectomy (AlphaVac/AngioVac) and NanoKnife, with NanoKnife recently showing strong double-digit growth and positive reimbursement decisions. The company is debt-free, generating positive cash flow and shifting production to Costa Rica to improve margins; CEO Jim Clemmer plans to retire at the end of 2026 and the board is seeking a successor. » Altro su de.investing.com
AngioDynamics to report quarterly results on July 14; analysts expect slightly improved EPS

AngioDynamics will release results for the most recent quarter on July 14, 2026. Three analysts expect an average EPS of -0.090 USD versus -0.150 USD in the year-ago quarter; revenue is forecast at about 80.2 million USD, virtually flat year‑over‑year (+0.1%). For the just-ended fiscal year, analysts on average see a loss of -0.162 USD per share and revenue of 314.1 million USD (prior year 292.5 million USD). » Altro su finanzen.net
AngioDynamics files patent lawsuit against Endovascular Engineering

AngioDynamics has filed a patent-infringement lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of Delaware, alleging that the Hēlo thrombectomy system infringes issued patents, including a self-expanding funnel technology. The company is seeking damages and injunctive relief and says it will vigorously defend its intellectual property rights. AngioDynamics also reported strong Q3 results (EPS -0.07 USD, revenue 78.4 million USD) and reaffirmed an adjusted EBITDA outlook for 2026; analysts responded with buy ratings but lowered price targets. The stock showed movements both after the quarterly results and in premarket trading. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Angiodynamics ha registrato ricavi pari a 74,34M€ e un utile netto di −9,79M€

(EUR)	mag 2026	YoY
Ricavi	+74,34M	5,25%
Utile lordo	+42,42M	14,02%
Utile netto	−9,79M	83,63%
EBITDA	−24,34M	1.355,60%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+556,73M€
Numero di azioni	41,33M
Massimo/minimo a 52 settimane	+13,98€ - +8,06€
Dividendi	No
Beta	0,32
Rapporto P/E	−17,83
Rapporto PEG	+1,49
Rapporto P/B	+3,81
Rapporto P/S	+2,03

Profilo aziendale

AngioDynamics, Inc. entwickelt, produziert und vertreibt verschiedene medizinische, chirurgische und diagnostische Geräte, die von professionellen Gesundheitsdienstleistern für die Behandlung von peripheren Gefäßerkrankungen und Gefäßzugängen sowie für den Einsatz in der Onkologie und in der Chirurgie in den Vereinigten Staaten und international verwendet werden. Das Unternehmen bietet NanoKnife-Ablationssysteme für die chirurgische Ablation von Weichteilen, Solero-Mikrowellen-Gewebeablationssysteme und Radiofrequenz-Ablationsprodukte für die Ablation solider krebsartiger oder gutartiger Tumore. Darüber hinaus bietet das Unternehmen BioSentry-Traktversiegelungssysteme, IsoLoc-Endorektal-Ballons, alatus-Vaginalballon-Packungssysteme, Angiographiekatheter, Führungsdrähte, perkutane Drainagekatheter und koaxiale Mikroeinführungskits an. Darüber hinaus bietet das Unternehmen Produkte für vaskuläre Interventionen und Therapien in den Bereichen Thrombusmanagement, Atherektomie, periphere Produkte (Core) und venöse Insuffizienz an. Darüber hinaus bietet das Unternehmen unter den Namen BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax und DuraMax peripher eingeführte Zentralkatheter, Midline-Katheter, implantierbare Ports, Dialysekatheter sowie entsprechendes Zubehör und Verbrauchsmaterial an, die in erster Linie zur kurzfristigen Verabreichung von Medikamenten, wie Chemotherapeutika und Antibiotika, in das zentrale Venensystem verwendet werden. Das Unternehmen verkauft und vermarktet seine Produkte an interventionelle Radiologen, interventionelle Kardiologen, Gefäßchirurgen, Urologen, interventionelle und chirurgische Onkologen und Intensivpfleger direkt sowie über Vertriebspartner. Das Unternehmen wurde 1988 gegründet und hat seinen Hauptsitz in Latham, New York.

Nome	Angiodynamics
CEO	James C. Clemmer
Sede centrale	Latham, ny Stati Uniti
Sito web	angiodynamics.com
Settore	Beni voluttuari
Industria	Beni durevoli per la casa
Quotazione in borsa	01/06/2004
Dipendenti	632